Stockscreener 앱 받기
15.98
5.48%
0.83
시간 외 거래:
15.88
-0.10
-0.63%
전일 마감가:
$15.15
열려 있는:
$15.265
하루 거래량:
43,513
Relative Volume:
0.05
시가총액:
$72.28M
수익:
-
순이익/손실:
$-24.77M
주가수익비율:
-21.89
EPS:
-0.73
순현금흐름:
$-17.36M
1주 성능:
+10.44%
1개월 성능:
-13.90%
6개월 성능:
+75.60%
1년 성능:
+94.97%
1일 변동 폭
$15.15
$16.15
1주일 범위
$14.35
$16.15
52주 변동 폭
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
INKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
15.98 | 68.52M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Trading Bots Trigger Alerts on MiNK Therapeutics Inc. Activity getLinesFromResByArray error: size == 0 - 더경남뉴스
Is MiNK Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Gains Summary & Safe Capital Allocation Plans - Newser
Using Python tools to backtest MiNK Therapeutics Inc. strategiesExit Point & Long Hold Capital Preservation Plans - Newser
Statistical indicators supporting MiNK Therapeutics Inc.’s strength2025 Bull vs Bear & Comprehensive Market Scan Reports - Newser
Will MiNK Therapeutics Inc. stock recover after recent dropTrade Analysis Summary & Safe Capital Allocation Plans - Newser
Analyzing net buyer seller activity in MiNK Therapeutics Inc.Trade Risk Report & Daily Profit Maximizing Tips - Newser
Applying Elliott Wave Theory to MiNK Therapeutics Inc.July 2025 Patterns & Capital Efficiency Focused Ideas - Newser
MiNK Therapeutics Inc. stock volume spike explained2025 Short Interest & Fast Gaining Stock Reports - Newser
Can MiNK Therapeutics Inc. hit a new high this monthProfit Target & Low Risk High Win Rate Stock Picks - Newser
Major Colorectal Cancer Trial Updates: Agenus to Present BATTMAN Phase 3 Study and BOT/BAL Data - Stock Titan
Can volume confirm reversal in MiNK Therapeutics Inc.July 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
Jobs Data: Is MiNK Therapeutics Inc. stock undervalued right nowBuy Signal & Reliable Momentum Entry Alerts - theviewers.co.kr
What is MiNK Therapeutics Inc. s P E ratio telling us2025 Institutional Moves & Safe Capital Growth Plans - theviewers.co.kr
Identifying reversal signals in MiNK Therapeutics Inc.2025 Earnings Impact & High Accuracy Investment Signals - Newser
What institutional flow reveals about MiNK Therapeutics Inc.July 2025 Spike Watch & Weekly Top Performers Watchlists - Newser
What moving averages say about MiNK Therapeutics Inc.2025 Market Trends & Accurate Buy Signal Alerts - Newser
New Zacks Rank #5 Stocks: MiNK Therapeutics, Mach Natural Resources, Canadian Solar - AInvest
New Strong Sell Stocks For August 22nd - Barchart.com
New Strong Sell Stocks for August 22nd - The Globe and Mail
Real time alert setup for MiNK Therapeutics Inc. performanceEarnings Recap Summary & Consistent Income Trade Ideas - Newser
When is the best time to exit MiNK Therapeutics Inc.July 2025 Recap & AI Based Trade Execution Alerts - Newser
Key resistance and support levels for MiNK Therapeutics Inc.2025 Price Momentum & Expert Approved Trade Ideas - Newser
Sector ETF Data Correlates with Strength in MiNK Therapeutics Inc.July 2025 Levels & Expert Curated Trade Setups - 클래시안
MiNK Therapeutics Cuts Q2 Cash Use 31% - AOL.com
Using portfolio simulators with MiNK Therapeutics Inc. included2025 Dividend Review & Free High Accuracy Swing Entry Alerts - Newser
Mink Therapeutics shares rise 2.29% intraday after Agenus announces strategic advancements in cancer treatment. - AInvest
Resistance Break Could Fuel MiNK Therapeutics Inc. Rally2025 Dividend Review & Safe Investment Capital Preservation Plans - newsimpact.co.kr
MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - MSN
What indicators show strength in MiNK Therapeutics Inc.Market Risk Summary & Daily Profit Focused Stock Screening - Newser
What high frequency data says about MiNK Therapeutics Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - Newser
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy Rating with $35 Price Target - AInvest
MiNK Therapeutics Upgraded to Buy by H.C. Wainwright Amid Upcoming Catalysts - AInvest
MiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnerships - MSN
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript - MSN
What momentum shifts mean for MiNK Therapeutics Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
MiNK Therapeutics: Strategic Momentum and Capital Raise Potential in a High-Stakes Biotech Landscape - AInvest
How to build a dashboard for MiNK Therapeutics Inc. stockQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - Newser
MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year - MSN
MiNK Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
MiNK Therapeutics shares rise 10.31% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics shares rise 8.77% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating - TipRanks
HC Wainwright Upgrades MiNK Therapeutics to Buy From Neutral - MarketScreener
MiNK Therapeutics upgraded to Buy from Neutral by HC Wainwright & Co., PT raised to $35. - AInvest
MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results - Investing.com Canada
MiNK Therapeutics Inc (INKT) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q2 2025 Milestones and Financials - TipRanks
MiNK Therapeutics Inc. Recovery Likely Here’s What Data Shows2025 Breakouts & Breakdowns & Free Technical Pattern Based Buy Signals - beatles.ru
MiNK Therapeutics (INKT) and the Strategic Value of AGENT-797 in Oncology and Immune-Mediated Diseases - AInvest
MiNK Therapeutics Q2 2025: Unraveling Key Contradictions in GvHD and ARDS Trial Strategies - AInvest
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):